Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The Metabolic Syndrome is a high prevalence disease worldwide. About a quarter of the adult
population suffers the disease.
Dapagliflozin is an inhibitor of the sodium-glucose co-transporter SGLT2 in the kidney and is
a novel treatment for diabetes type 2. Some studies indicate that SGLT2 inhibitors have
benefits on blood pressure, triglycerides levels and help to raise the levels of high density
lipoproteins cholesterol (c-HDL).
The aim of this study is to evaluate the effect of dapagliflozin on metabolic syndrome,
insulin sensitivity and insulin secretion.
The investigators hypothesis is that the administration of dapagliflozin modifies the
metabolic syndrome, insulin sensitivity and insulin secretion.